

GETTING STARTED WITH FABHALTA

Help your eligible patients start and stay on treatment



Doctor and patient portrayal.

What you will find in this guide

FABHALTA coverage

How to enroll in FABHALTA REMS and get started with vaccinations and antibiotic prophylaxis

Novartis Patient Support

REMS, Risk Evaluation and Mitigation Strategy.

INDICATIONS

FABHALTA is indicated for:

- The reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g.
This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether FABHALTA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.
- The treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA

FABHALTA, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type b. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.

- Complete or update vaccinations for encapsulated bacteria at least 2 weeks prior to the first dose of FABHALTA, unless the risks of delaying therapy with FABHALTA outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria in patients receiving a complement inhibitor.
- Patients receiving FABHALTA are at increased risk for invasive disease caused by encapsulated bacteria, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious infections and evaluate immediately if infection is suspected.

Because of the risk of serious infections caused by encapsulated bacteria, FABHALTA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the FABHALTA REMS.

Please [click here](#) for full Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and [Medication Guide](#).



COVERAGE

GETTING STARTED

NOVARTIS PATIENT SUPPORT

IMPORTANT SAFETY
INFORMATION

FABHALTA insurance coverage

Real-world coverage data show broad insurance access for patients with IgAN and C3G

Coverage in IgAN



Patient portrayal.

[85%] of patients with private insurance have coverage for FABHALTA*

[97%] of FABHALTA prescriptions filled have **[less than]** a **[\$10]** out-of-pocket cost for patients with IgAN†

Coverage in C3G



Patient portrayal.

[85%] of patients with private insurance have coverage for FABHALTA*

[98%] of FABHALTA prescriptions filled have **[less than]** a **[\$10]** out-of-pocket cost for patients with C3G‡

*As of December 2025.

†Source: Specialty Pharmacy Data from August 2024 to November 2025; n=1989, which represents approximately 98% of FABHALTA fills. For remaining patients, the out-of-pocket cost for the product varies and may be as high as the total cost of the product.

‡Source: Specialty pharmacy data from March 2025 to November 2025; n=491, which represents approximately 99% of FABHALTA fills. For remaining patients, the out-of-pocket cost for the product varies and may be as high as the total cost of the product. C3G, complement 3 glomerulopathy; IgAN, immunoglobulin A nephropathy.

Please [click here](#) for full Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and [Medication Guide](#).

 **FABHALTA**[®]
(iptacopan) 200 mg capsules



COVERAGE

GETTING STARTED

NOVARTIS PATIENT SUPPORT

IMPORTANT SAFETY INFORMATION

Getting your patients started on FABHALTA



REMS certification

Because of the risk of serious infections caused by encapsulated bacteria, you will need to become certified in the FABHALTA REMS and fulfill its requirements.

Enroll in the FABHALTA REMS:

- **Review** the FABHALTA Prescribing Information and REMS materials
- **Submit** the completed Prescriber Enrollment form online at www.FABHALTA-REMS.com or by fax to [1-877-206-3255](tel:1-877-206-3255)

After enrollment:

- **Counsel** patients on the risk of serious infections caused by encapsulated bacteria, vaccination requirements, and early signs and symptoms of serious infections
- **Provide** patients with REMS educational materials and the Patient Safety Card
- **Instruct** patients to always carry the card during treatment and for 2 weeks following the last dose of FABHALTA

FABHALTA, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type b. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life threatening or fatal if not recognized and treated early.

For more information, call [1-833-99FABHA](tel:1-833-99FABHA) or visit www.FABHALTA-REMS.com.



Vaccination and/or antibiotic prophylaxis

Required vaccinations: *Streptococcus pneumoniae* and *Neisseria meningitidis* (serogroups A, C, W, Y, and B). Complete or update vaccination against encapsulated bacteria (according to the most current ACIP recommendations for patients receiving a complement inhibitor) at least 2 weeks before starting FABHALTA, unless the risks of delaying FABHALTA outweigh the risk of developing a serious infection.

If urgent FABHALTA therapy is indicated in a patient who is not up to date with these vaccines:

- **Provide** the patient with antibacterial drug prophylaxis and administer these vaccines according to ACIP recommendations as soon as possible. For additional details on antibacterial drug prophylaxis, please see the FABHALTA Prescribing Information, Warnings and Precautions (Section 5.1)

During treatment with FABHALTA:

As vaccination does not eliminate the risk of serious encapsulated bacterial infections, closely monitor patients for early signs and symptoms. Inform patients of these signs and symptoms, and instruct patients to seek immediate medical care if they occur.

- **Evaluate** and treat immediately if infection is suspected, as serious infection may rapidly become life threatening or fatal if not recognized and treated early. Promptly treat known infections
- **Consider** interruption of FABHALTA in patients who are receiving treatment for serious infections, depending on the risks of interrupting treatment in the disease being treated
- **While on therapy**, patients are required to be revaccinated as needed



FABHALTA prescription

Prescribing FABHALTA through a limited network of specialty pharmacies

Once you are ready to prescribe FABHALTA, inform your patient which specialty pharmacy in the limited network will be dispensing their FABHALTA prescription.*

Submit Rx by downloading and completing a **Start Form with Novartis Patient Support**, a comprehensive program that offers assistance to health care professionals and patients for getting started on FABHALTA.

- Start Form: FABHALTA-startform.com
- Phone: [1-833-99FABHA](tel:1-833-99FABHA)
- Fax: [1-877-44FABHA](tel:1-877-44FABHA)

OR

Send the Rx directly to 1 of the limited network of specialty pharmacies.

CareMed†

- Website: caremed.com
- Phone: [1-877-227-3405](tel:1-877-227-3405)
- Fax: [1-877-542-2731](tel:1-877-542-2731)

Biologics by McKesson

- Website: biologics.mckesson.com
- Phone: [1-800-850-4306](tel:1-800-850-4306)
- Fax: [1-800-823-4506](tel:1-800-823-4506)

*Inform your patient which specialty pharmacy will be dispensing their FABHALTA prescription, and tell them to expect a phone call to arrange delivery of their prescription.

†Pharmacies that dispense FABHALTA must be certified in the FABHALTA REMS and must verify that prescribers are certified.

†CareMed is a subsidiary of Onco360.

ACIP, Advisory Committee on Immunization Practices; Rx, prescription.

Please [click here](#) for full Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and [Medication Guide](#).



COVERAGE

GETTING STARTED

NOVARTIS PATIENT SUPPORT

IMPORTANT SAFETY INFORMATION

REMS certification

REMS certification is a one-time process



REMS certification

Because of the risk of serious infections caused by encapsulated bacteria, you will need to become certified in the FABHALTA REMS and fulfill its requirements.

Enroll in the FABHALTA REMS:

- **Review** the FABHALTA Prescribing Information and REMS materials
- **Submit** the completed prescriber enrollment form online at [www.FABHALTA-REMS.com] or by fax to [[1-877-206-3255](tel:1-877-206-3255)]

After enrollment:

- **Counsel** patients on the risk of serious infections caused by encapsulated bacteria, vaccination requirements, and early signs and symptoms of serious infections
- **Provide** patients with REMS educational materials and the Patient Safety Card
- **Instruct** patients to always carry the card during treatment and for 2 weeks following the last dose of FABHALTA

FABHALTA, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type b. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life threatening or fatal if not recognized and treated early.



Vaccination and/or antibiotic prophylaxis



FABHALTA prescription

Scan this QR code to get started

- For more information, view the full REMS program details and requirements at [www.FABHALTA-REMS.com]
- For any certification questions, contact the REMS Coordinating Center at [[1-833-99FABHA](tel:1-833-99FABHA)]



Please [click here](#) for full Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and [Medication Guide](#).

 **FABHALTA**[®]
(iptacopan) 200 mg capsules



COVERAGE

GETTING STARTED

NOVARTIS PATIENT SUPPORT

IMPORTANT SAFETY INFORMATION

Vaccination and/or antibiotic prophylaxis

Make the appropriate choice for your patient



REMS certification



Vaccination and/or antibiotic prophylaxis



FABHALTA prescription

Required vaccinations: *Streptococcus pneumoniae* and *Neisseria meningitidis* (serogroups A, C, W, Y, and B). Complete or update vaccination against encapsulated bacteria (according to the most current ACIP recommendations for patients receiving a complement inhibitor) at least 2 weeks before starting FABHALTA, unless the risks of delaying FABHALTA outweigh the risk of developing a serious infection.

If urgent FABHALTA therapy is indicated in a patient who is not up to date with these vaccines:

- **Provide** the patient with antibacterial drug prophylaxis and administer these vaccines according to ACIP recommendations as soon as possible. For additional details on antibacterial drug prophylaxis, please see the FABHALTA Prescribing Information, Warnings and Precautions (Section 5.1)

During treatment with FABHALTA:

As vaccination does not eliminate the risk of serious encapsulated bacterial infections, closely monitor patients for early signs and symptoms. Inform patients of these signs and symptoms, and instruct patients to seek immediate medical care if they occur.

- **Evaluate** and treat immediately if infection is suspected, as serious infection may rapidly become life threatening or fatal if not recognized and treated early. Promptly treat known infections
- **Consider** interruption of FABHALTA in patients who are receiving treatment for serious infections, depending on the risks of interrupting treatment in the disease being treated
- **While on therapy**, patients are required to be revaccinated as needed

Vaccinations are **REQUIRED** to be completed or updated at least 2 weeks before starting FABHALTA against:

✓ *Streptococcus pneumoniae*

✓ *Neisseria meningitidis*
(serogroups A, C, W, Y, and B)

Is your patient fully vaccinated?*

YES

NO

Start FABHALTA

Complete required vaccinations, wait at least 2 weeks, then start FABHALTA

If urgent treatment with FABHALTA is required at any point, provide antibiotic prophylaxis + FABHALTA and administer these vaccines as soon as possible

*Patients must wait at least 2 weeks since the last required vaccination dose was administered prior to starting FABHALTA.

For additional details on antibacterial drug prophylaxis, please see the FABHALTA Prescribing Information, Warnings and Precautions (Section 5.1).

Please [click here](#) for full Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and [Medication Guide](#).

 **FABHALTA**[®]
(iptacopan) 200 mg capsules



COVERAGE

GETTING STARTED

NOVARTIS PATIENT SUPPORT

IMPORTANT SAFETY INFORMATION

FABHALTA prescription

Choose 1 of 2 ways to submit Rx



REMS certification



Vaccination and/or antibiotic prophylaxis



FABHALTA prescription

There are 2 ways to submit a FABHALTA prescription

How to get started:

- Submit your prescription through a specialty pharmacy directly OR Novartis Patient Support
- Work with the specialty pharmacy OR Novartis Patient Support to determine your patient's coverage and available affordability support

IMPORTANT:

Be prepared to provide the necessary information for insurance approval. Make sure patients understand that the specialty pharmacy will be contacting them and that they need to speak with the pharmacy directly to receive their FABHALTA medication.

Choose 1 of 2 ways to submit Rx

Submit the Rx directly to 1 of the 2 limited-network specialty pharmacies*



CareMed

Website: caredmed.com
Phone: 1-877-227-3405
Fax: 1-877-542-2731

OR



Biologics by McKesson

Website: biologics.mckesson.com
Phone: 1-800-850-4306
Fax: 1-800-823-4506

Complete the Start Form with Novartis Patient Support

Please visit www.FABHALTA-startform.com to download the Start Form
Phone: [1-833-99FABHA]
Fax: [1-877-44FABHA]

OR

Fill out and submit the Start Form electronically at CoverMyMeds.health

*Inform your patients which specialty pharmacy will be dispensing their FABHALTA prescription, and tell them to expect a phone call to arrange delivery of their prescription. Pharmacies that dispense FABHALTA must be certified in the FABHALTA REMS and must verify that prescribers are certified.

Please [click here](#) for full Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and [Medication Guide](#).

 **FABHALTA**[®]
(iptacopan)^{200 mg capsules}



A dedicated team for you and your patients

Novartis Patient Support is a comprehensive program that can help your eligible patients start and stay on treatment

We can help support you and your patients throughout their journey with the following:



Insurance support

Help navigating the insurance process, including benefits verification and support with the prior authorization and appeals processes.



Financial support

Assistance with connecting patients to available saving options. Inform your eligible patients about Co-Pay Plus.* Privately insured patients may pay as little as [\$0] for FABHALTA. Patients with commercial insurance coverage for FABHALTA may receive up to [\$1,000] for qualifying vaccination costs (excluding administrative fees). Once their insurance coverage is confirmed, your patients can start using their Co-Pay Plus* card to help cover out-of-pocket costs



Vaccination support[†]

Our [dedicated Novartis Patient Support team] offers support to help your patients locate vaccinations. **See the next page for more information about vaccination support with FABHALTA.**



Ongoing support

A [dedicated Novartis Patient Support team] and educational resources can help your patients get started on treatment and support them along the way.

Eligible patients can receive up to 12 months of FABHALTA for free while coverage is pursued.[‡]

GET YOUR PATIENTS STARTED AT FABHALTA-STARTFORM.COM

[*Co-Pay Plus:] Limitations apply. Patients with commercial insurance coverage for FABHALTA may receive up to [\$20,000] in annual co-pay benefits for the cost of FABHALTA and up to [\$1,000] for qualifying vaccination costs (excluding administrative fees). Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient's insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited toward patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States, Puerto Rico, and select territories. Void where prohibited by law. Additional restrictions may apply. This program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

[†Vaccination support:] Limitations apply. Please contact Novartis Patient Support at [1-833-99FABHA (1-833-993-2242)] for more information.

[‡Bridge Program:] Limitations apply. Patients with commercial insurance, a valid prescription for FABHALTA, and a denial of insurance coverage based on a prior authorization requirement may receive a monthly maintenance dose for up to [12 months] or until insurance coverage approval, whichever occurs first. Not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state program, or where prohibited by law. A prior authorization and/or appeal of coverage denial must be submitted within [90 days] to remain in the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Additional restrictions may apply. Novartis reserves the right to rescind, revoke, or amend the Program without notice.

Please [click here](#) for full Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and [Medication Guide](#).



Getting started with vaccination support

Our dedicated Novartis Patient Support team offers support to help patients get the vaccinations they need

The Vaccination Support program* provides in-home vaccination and guided navigation to help simplify the process for eligible patients, regardless of insurance.



In-home vaccination

We can help schedule in-home administration appointments for your eligible patients at no cost.



Guidance throughout the vaccination process

We can also help patients find their local vaccination locations and offer guidance on accessing existing vaccination records.



Enroll with the FABHALTA Start Form

You can enroll your patients in Vaccination Support using the FABHALTA Start Form to further explain the vaccination offerings that may be available to them. Novartis Patient Support will connect your eligible patients with their preferred vaccination services.

For more information on our Vaccination Support offerings, call Novartis Patient Support at [1-833-99FABHA (1-833-993-2242), Monday through Friday, 8:00 AM to 8:00 PM ET, excluding holidays.]

[*Vaccination Support:] Limitations apply. Please contact Novartis Patient Support at [1-833-99FABHA (1-833-993-2242)] for more information.

Please [click here](#) for full Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and [Medication Guide](#).



Indications and Important Safety Information

INDICATIONS

FABHALTA is indicated for:

- The reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g.
This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether FABHALTA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.
- The treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA

FABHALTA, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type b. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.

- Complete or update vaccinations for encapsulated bacteria at least 2 weeks prior to the first dose of FABHALTA, unless the risks of delaying therapy with FABHALTA outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria in patients receiving a complement inhibitor.
- Patients receiving FABHALTA are at increased risk for invasive disease caused by encapsulated bacteria, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious infections and evaluate immediately if infection is suspected.

Because of the risk of serious infections caused by encapsulated bacteria, FABHALTA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the FABHALTA REMS.

CONTRAINDICATIONS

- In patients with serious hypersensitivity to FABHALTA or any of the excipients.
- For initiation in patients with unresolved serious infection caused by encapsulated bacteria, including *Streptococcus pneumoniae*, *Neisseria meningitidis*, or *Haemophilus influenzae* type b.

WARNINGS AND PRECAUTIONS

Serious Infections Caused by Encapsulated Bacteria

- FABHALTA, a complement inhibitor, increases a patient's susceptibility to serious, life-threatening, or fatal infections caused by encapsulated bacteria, including *Streptococcus pneumoniae*, *Neisseria meningitidis* (caused by any serogroup, including nongroupable strains), and *Haemophilus influenzae* type b. Life-threatening and fatal infections with encapsulated bacteria have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. The initiation of FABHALTA is contraindicated in patients with unresolved serious infections caused by encapsulated bacteria.

ADDITIONAL IMPORTANT SAFETY INFORMATION

Please [click here](#) for full Prescribing Information, including Boxed WARNING and [Medication Guide](#).

 **FABHALTA**[®]
(iptacopan) 200 mg capsules



Important Safety Information (continued)

WARNINGS AND PRECAUTIONS (continued)

Serious Infections Caused by Encapsulated Bacteria (continued)

- Complete or update vaccination against encapsulated bacteria at least 2 weeks prior to the start of FABHALTA, according to the current ACIP recommendations for patients receiving a complement inhibitor. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with FABHALTA. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent FABHALTA therapy is indicated in a patient who is not up-to-date with vaccinations against encapsulated bacteria according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible. The benefits and risks of treatment with FABHALTA, as well as the benefits and risks of antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by encapsulated bacteria.
- Vaccination does not eliminate the risk of serious encapsulated bacterial infections, despite development of antibodies following vaccination. Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if they occur. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of FABHALTA in patients who are undergoing treatment for serious infections, depending on the risks of interrupting treatment in the disease being treated.

FABHALTA REMS

- FABHALTA is available only through a restricted program under a REMS called FABHALTA REMS because of the risk of serious infections caused by encapsulated bacteria.
- Under the FABHALTA REMS, prescribers must enroll in the program; counsel patients about the risks, signs, and symptoms of serious infections caused by encapsulated bacteria; provide patients with the REMS educational materials; ensure patients are vaccinated against encapsulated bacteria; prescribe antibacterial drug prophylaxis if patients' vaccination status is not up-to-date and treatment must be started urgently; and provide instructions to always carry the Patient Safety Card during treatment and for 2 weeks following the last dose of FABHALTA.
- Further information is available by telephone: [1-833-993-2242] or online at [www.FABHALTA-REMS.com].

Hyperlipidemia

- FABHALTA may increase total cholesterol, LDL cholesterol, and serum triglycerides. In clinical trials, some patients required cholesterol-lowering medications.
- Monitor serum lipid parameters periodically during treatment with FABHALTA and initiate cholesterol-lowering medications, if indicated.

ADVERSE REACTIONS

- The most common adverse reactions ($\geq 5\%$) in adults with IgAN receiving FABHALTA were upper respiratory tract infection, lipid disorder, and abdominal pain.
- The most common adverse reactions ($\geq 10\%$) in adults with C3G receiving FABHALTA were nasopharyngitis and viral infection.

ADDITIONAL IMPORTANT SAFETY INFORMATION

Please [click here](#) for full Prescribing Information, including Boxed WARNING and [Medication Guide](#).

 **FABHALTA**[®]
(iptacopan) 200 mg capsules

10



COVERAGE

GETTING STARTED

NOVARTIS PATIENT SUPPORT

IMPORTANT SAFETY
INFORMATION

Important Safety Information (continued)

DRUG INTERACTIONS

- Concomitant use of CYP2C8 inducers (eg, rifampin) may decrease iptacopan exposure, which may result in loss of or reduced efficacy of FABHALTA. Monitor the clinical response and discontinue use of the CYP2C8 inducer if loss of efficacy of FABHALTA is evident.
- Concomitant use of strong CYP2C8 inhibitors (eg, gemfibrozil) may increase iptacopan exposure, which may result in an increased risk for adverse reactions with FABHALTA. Coadministration with a strong CYP2C8 inhibitor is not recommended.

USE IN SPECIFIC POPULATIONS

- Because of the potential for serious adverse reactions in a breastfed child, breastfeeding should be discontinued during treatment and for 5 days after the final dose.
- FABHALTA is not recommended in patients with severe hepatic impairment (Child-Pugh class C). No dose adjustment is required for patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment.

Please [click here](#) for full Prescribing Information, including Boxed WARNING and [Medication Guide](#).

 **FABHALTA**[®]
(iptacopan) 200 mg capsules

11



COVERAGE

GETTING STARTED

NOVARTIS PATIENT SUPPORT

IMPORTANT SAFETY
INFORMATION



FABHALTA[®]
(iptacopan) 200 mg capsules

HELP PATIENTS GET STARTED ON FABHALTA



LEARN MORE ABOUT FABHALTA COVERAGE
at www.FABHALTA-HCP.com/local-coverage



ENROLL IN REMS
at www.FABHALTA-REMS.com



DOWNLOAD THE START FORM
at www.FABHALTA-startform.com

Questions?

For more information on educational resources, call **Novartis Patient Support** at [1-833-99FABHA \(1-833-993-2242\)](tel:1-833-99FABHA),
[Monday through Friday, 8:00 AM-8:00 PM ET](tel:1-833-99FABHA).

Please [click here](#) for full Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and [Medication Guide](#).



Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

© 2026 Novartis

11/25

FA-11543497



COVERAGE

GETTING STARTED

NOVARTIS PATIENT SUPPORT

IMPORTANT SAFETY
INFORMATION